Everest Medicines Limited (HKG: 1952) has entered into an asset acquisition agreement with Corxel Pharmaceuticals Limited (CORXEL) to secure development, commercialization, and localized production rights for Etripamil nasal spray (US: CARDAMYST) in Greater China – a USD 50 million transaction that delivers the first FDA‑approved acute PSVT therapy in over 30 years to Everest’s cardiovascular portfolio ahead of anticipated NMPA approval in Q3 2026.
Transaction Overview
Item
Detail
Acquirer
Everest Medicines Limited (HKG: 1952)
Seller
Corxel Pharmaceuticals Limited (CORXEL)
Product
Etripamil nasal spray (US trade name: CARDAMYST)
Territory
Greater China (Mainland China, Hong Kong, Macau, Taiwan)
Upfront Payment
USD 30 million
Milestone Payment
USD 20 million (upon development milestones)
Total Consideration
USD 50 million
Rights Acquired
Development, commercialization, localized production
Assumed Obligations
License/sub‑agreement rights from Corxel’s May 2021 Milestone Pharma deal (excluding certain liabilities)
Product Profile – Etripamil
Attribute
Specification
Clinical Advantage
Mechanism
Novel, fast‑acting calcium channel blocker
Rapid termination of PSVT episodes
Formulation
Portable nasal spray
Self‑administration at home; eliminates emergency department visits
Onset
Rapid onset of action
Symptom relief within minutes
Tolerability
Good safety profile
Suitable for outpatient/ambulatory use
Accessibility
Home‑based self‑treatment
High patient convenience; reduced healthcare system burden
Regulatory Timeline & Market Context
Milestone
Date
Status
Corxel‑Milestone License
May 2021
Exclusive Greater China rights obtained by Corxel
FDA Approval
December 2025
First PSVT therapy approved in US in 30+ years
NMPA NDA Acceptance
January 17, 2025
Under review
NMPA Approval Expected
Q3 2026
Imminent China market entry
Everest Acquisition Closing
2026 (anticipated)
Integration and launch preparation
Strategic Rationale & Market Impact
Dimension
PSVT Treatment Landscape
Etripamil Value Proposition
Current Standard
Vagal maneuvers (limited efficacy); emergency department adenosine/verapamil IV administration
At‑home acute treatment eliminates ED visits; patient‑empowered management
Unmet Need
~2 million PSVT episodes annually in China; 70‑80% require ED intervention; high patient anxiety and healthcare costs
No approved acute PSVT pharmacotherapy in China; off‑label calcium channel blocker use
First‑in‑class positioning with 5‑7 year market exclusivity potential
Everest Portfolio Fit
Adds cardiovascular/rare disease asset to infectious disease and oncology focus
Diversification into high‑value acute care; leverages hospital/GI relationships
Commercial Outlook
China PSVT Market Dynamics: Estimated 1.5‑2 million diagnosed PSVT patients in China; acute episode frequency 2‑4 episodes/patient/year; addressable market RMB2‑3 billion annually assuming 30‑40% patient penetration and RMB300‑500 per episode pricing; Etripamil’s home‑use positioning supports premium pricing vs. generic off‑label alternatives.
Everest Execution Advantage: Acquisition of NDA‑stage asset (vs. early‑development licensing) de‑risks timeline and investment; Q3 2026 NMPA approval enables H2 2026 launch with immediate revenue recognition; localized production rights support cost optimization and supply security vs. import dependency.
Corxel Exit Rationale: USD 50 million monetization of licensed‑in asset (originally from Milestone Pharma) provides return on 4‑year development investment; Corxel likely retains other pipeline assets or focuses on core therapeutic areas.
Milestone Pharma Partnership: Original US developer (NASDAQ: MIST) retains ex‑Greater China rights; Everest acquisition validates China market attractiveness for US biotech; potential for regulatory synergy (FDA approval supports NMPA review) and physician education collaboration.
Competitive Defensibility: 30‑year innovation gap in PSVT acute therapy creates first‑mover advantage; nasal spray formulation complexity (device + formulation) provides manufacturing barrier to entry; Everest’s 5‑year exclusivity (orphan drug designation potential) supports sustainable returns.
Forward‑Looking Statements This brief contains forward‑looking statements regarding NMPA approval timelines, commercialization expectations, and market penetration projections for Etripamil in Greater China. Actual results may differ due to regulatory review outcomes, manufacturing scale‑up challenges, and competitive dynamics in the cardiovascular therapeutics market.-Fineline Info & Tech
By Fineline Cube